Zevra Therapeutics, Inc. (ZVRA): EBITDA
-$58.89M
Year ended 2025-12-31
$83.87M
Trailing 12 months to 2026-06-30
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$58.89M | n/m | 2026-03-09, From 2025-01-01 |
| 2024-12-31 | -$80.61M | n/m | 2026-03-09, From 2024-01-01 |
| 2023-12-31 | -$48.60M | n/m | 2025-03-12, From 2023-01-01 |
| 2022-12-31 | -$41.62M | n/m | 2024-04-01, From 2022-01-01 |
| 2021-12-31 | $7.99M | n/m | 2023-03-07, From 2021-01-01 |
| 2020-12-31 | -$5.34M | n/m | 2022-03-31, From 2020-01-01 |
| 2019-12-31 | -$20.03M | n/m | 2021-03-12, From 2019-01-01 |
| 2018-12-31 | -$55.58M | n/m | 2020-02-28, From 2018-01-01 |
| 2017-12-31 | -$33.03M | n/m | 2019-03-01, From 2017-01-01 |
| 2016-12-31 | -$37.31M | n/m | 2018-03-30, From 2016-01-01 |
| 2015-12-31 | -$22.73M | n/m | 2018-03-30, From 2015-01-01 |
| 2014-12-31 | -$16.37M | n/m | 2017-03-10, From 2014-01-01 |
| 2013-12-31 | -$4.65M | n/a | 2016-03-16, From 2013-01-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| Zevra Therapeutics, Inc. (ZVRA) | 2025-12-31 | -$58.89M | n/m |
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | -$124.56M | n/m |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $13.97M | -21.1% |
| Siga Technologies Inc (SIGA) | 2025-12-31 | $24.26M | -65.6% |
| Xencor Inc (XNCR) | 2025-12-31 | -$166.99M | n/m |
| Cytokinetics Inc (CYTK) | 2025-12-31 | -$602.13M | n/m |
| Lifecore Biomedical, Inc. (LFCR) | 2025-05-25 | -$9.22M | n/m |
| Standard Biotools Inc. (LAB) | 2025-12-31 | -$100.99M | n/m |
| ARS Pharmaceuticals, Inc. (SPRY) | 2025-12-31 | -$178.08M | n/m |
Compare ZVRA, URGN, GYRE, SIGA side by side · Screen every company in Pharmaceutical Preparations ↗